Allogeneic stem cell transplantation reduces the relapse incidence in patients with AML and normal karyotype independently of the FLT3-ITD status

被引：0
|
作者：
Schueller, F.
Maschmeyer, G.
Fischer, T.
Herold, M.
Sayer, H. G.
Wolf, H. -H.
Kreibich, U.
Haehling, D.
Doelken, G.
Junghanss, C.
Grobe, N.
Krahl, R.
Lange, T.
Al Ali, H. -K.
Basara, N.
Poenisch, W.
Niederwieser, D.
机构：
来源：
BONE MARROW TRANSPLANTATION | 2010年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S39 / S40
页数：2
相关论文
共 50 条
  • [1] Reduction of Relapse Incidence and improvement of Leukemia Free Survival by Allogeneic Stem Cell Transplantation in Patients with AML and Normal Karyotype Irrespective of the FLT3-ITD Status.
    Schueler, Frank
    Basara, Nadezda
    Maschmeyer, Georg
    Fischer, Thomas
    Herold, Michael
    Sayer, Herbert G.
    Wolf, Hans-Heinrich
    Kreibich, Ute
    Haehling, Detlev
    Doelken, Gottfried
    Junghanss, Christian
    Grobe, Norbert
    Krahl, Rainer
    Al-Ali, Haifa Kathrin
    Poenisch, Wolfram
    Niederwieser, Dietger
    BLOOD, 2009, 114 (22) : 644 - 644
  • [2] Impact of FLT3-ITD Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
    Grillo, Giovanni
    Zucchetti, Elisa
    Inzoli, Elena
    Mancini, Valentina
    Forno, Barbara
    Lotesoriere, Ivana
    Bertani, Giambattista
    Cairoli, Roberto
    BLOOD, 2017, 130
  • [3] Response: Allogeneic stem cell transplantation and FLT3/ITD status in AML
    Gale, Rosemary E.
    Hills, Robert
    Wheatley, Keith
    Burnett, Alan K.
    Linch, David C.
    BLOOD, 2006, 108 (01) : 400 - 401
  • [4] Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML
    Li Wan
    Shuqi Ding
    Mimi Xu
    Kangkang Lv
    Yuanyuan Du
    Depei Wu
    Mingzhu Xu
    Yuejun Liu
    International Journal of Hematology, 2022, 116 : 731 - 743
  • [5] Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML
    Wan, Li
    Ding, Shuqi
    Xu, Mimi
    Lv, Kangkang
    Du, Yuanyuan
    Wu, Depei
    Xu, Mingzhu
    Liu, Yuejun
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (05) : 731 - 743
  • [6] Improvement of leukemia-free survival (ITS) and reduction of relapse incidence by allogeneic stem cell transplantation (SCT) in elderly patients (pts) with AML, irrespective of the FLT3-ITD and npm status except npm+/flt3(ITD)-
    Niederwieser, O.
    Schueler, F.
    Hegenbart, U.
    Maschmeyer, G.
    Fischer, T.
    Junghanss, C.
    Wolf, H.
    Sayer, H. G.
    Kreibich, U.
    Doelken, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
    Iannotta, R.
    Celentano, M.
    Marotta, S.
    Pedata, C. M.
    Riccardi, C.
    Migliaccio, I.
    Viola, A.
    Muggianu, S. M.
    Falco, C.
    Bovenzi, D.
    Ferrara, F.
    Picardi, A.
    LEUKEMIA RESEARCH REPORTS, 2022, 18
  • [8] Prolonged Remission of FLT3-ITD Positive AML Treated With Sorafenib Post Allogeneic Stem Cell Transplantation
    Moukadem, Hiba
    Antar, Ahmad
    Kharfan-Dabaja, Mohamed
    Bazarbachi, Ali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S126 - S127
  • [9] Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML
    Chen, Yi-Bin
    Shuli, Li
    Andrew, Lane A.
    Connolly, Christine
    Del Rio, Candice
    Valles, Betsy
    Curtis, Morgan
    Ballen, Karen K.
    Cutler, Corey S.
    Dey, Bimalangshu R.
    El-Jawahri, Areej
    Fathi, Amir T.
    Ho, Vincent T.
    Joyce, Amy
    McAfee, Steven L.
    Rudek, Michelle A.
    Rajkhowa, Trivikram
    Verselis, Sigitas
    Antin, Joseph H.
    Spitzer, Thomas R.
    Levis, Mark
    Soiffer, Robert J.
    BLOOD, 2014, 124 (21)
  • [10] ADVERSE PROGNOSIS OF LOW AR FLT3-ITD IN AML AND CLINICAL BENEFIT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN AML PATIENTS WITH LOW AR FLT3-ITD AND NPM1
    Kim, Hyeoung-Joon
    Kim, TaeHyung
    Kook, Hoon
    Song, Ga-Young
    Ahn, Seo-Yeon
    Jung, Sung-Hoon
    Kim, Mihee
    Yang, Deok-Hwan
    Lee, Je-Jung
    Choi, Seung Hyun
    Kim, Mi Yeon
    Jung, Chul Won
    Jang, Jun-Ho
    Kim, Hee Je
    Moon, Joon Ho
    Sohn, Sang Kyun
    Won, Jong-Ho
    Park, Seong-Kyu
    Kim, Sung-Hyun
    Zhang, Zhaolei
    Ahn, Jae-Sook
    Kim, Dennis Dong Hwan
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 172 - 173
12345